Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Moderna woos trial vet Melanie Ivarsson to the senior R&D team; Ex-Roche CMO Sandra Horning joins Gilead board
6 years ago
Peer Review
Hahn stresses importance of data, RWE in first all-hands meeting
6 years ago
FDA+
Black Diamond doubles in value hours into Nasdaq debut, marking hot start to the 2020 IPO run
6 years ago
Financing
Don't get too excited about Eli Lilly's upcoming Alzheimer's readout just yet, R&D chief cautions
6 years ago
R&D
Resistant to CAR-T therapies? It's the cancer, not your immune system — study
6 years ago
R&D
Cell/Gene Tx
Doudna-founded CRISPR upstart bags $45M for new Cas research, extends its reach into therapeutics
6 years ago
Financing
With deals in tow, Roche ends 2019 with five discarded programs
6 years ago
R&D
The second, first AI developed drug enters the clinic; Aprea gets breakthrough status for myelodysplastic syndromes ...
6 years ago
News Briefing
Vas Narasimhan wants Novartis to have a big focus on China. Here’s what that looks like
6 years ago
China
Pharma
Eli Lilly notches another positive baricitinib eczema trial, but has Dermira made it obsolete?
6 years ago
R&D
Josh Bilenker’s team at Eli Lilly chops 3 cancer drug programs in pipeline cleanup as their $1.6B IL-10 effort ...
6 years ago
R&D
FDA outlines product development process to combat Wuhan coronavirus
6 years ago
FDA+
Coronavirus
Rani Therapeutics eyes potential IPO as robotic pill technology takes shape
6 years ago
R&D
Sanofi polishes rare disease profile as Niemann-Pick drug scores promising PhII/III data — there's just one ...
6 years ago
R&D
Cancer-focused Black Diamond vaults on to Nasdaq in $200M+ public debut, marking biggest biotech IPO in 2020 so far
6 years ago
Financing
'What's he going to do? He's going to date his wife more!' Steve Holtzman on Decibel and leaving biotech (again)
6 years ago
People
The first drug from Eli Lilly's new-look oncology group gets speedy review as Bilenker's team hones focus
6 years ago
R&D
Sanofi stops all but the most urgent trips to China; Flurry of orphan drug designations arrive
6 years ago
News Briefing
Novartis rethinks CML strategy for next-gen allosteric drug due for a pivotal readout later this year
6 years ago
R&D
What in the world is a MINOR CRL, Amphastar?
6 years ago
R&D
FDA+
Patient dies in a troubled HBV drug program — forcing developers to scrap the drug and shift focus. To STING
6 years ago
R&D
Putting buybacks on hold, Pfizer’s CEO is plotting a string of important PhII deals in the year ahead. You’ve ...
6 years ago
R&D
How do American scientists get embroiled in China scandals? Moffitt investigation sheds some light
6 years ago
People
China
Laurence Reid returns as CEO of Decibel Therapeutics — as Steve Holtzman retires
6 years ago
People
First page
Previous page
866
867
868
869
870
871
872
Next page
Last page
Confirm Profile
Full Name
Email
Company
Job Title
{@!--CONSENT--!@}
Submit